Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity

British Journal of Pharmacology

Volumn 160, Issue 5, 2010, Pages 1045-1047

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Agonism; Allosterism; Functional selectivity; Receptor selectivity

Indexed keywords

1,6 HEXAMETHYLENEBIS[DIMETHYL(3 PHTHALIMIDOPROPYL)AMMONIUM BROMIDE]; CARBACHOL; CYTOSOL RECEPTOR; CYTOSOLIC SIGNALLING PROTEIN; MEMBRANE RECEPTOR; METHYLSCOPOLAMINE; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; LIGAND; SEVEN-TRANSMEMBRANE G-PROTEIN-COUPLED RECEPTOR;

AGONIST; ALLOSTERISM; CELL FREE SYSTEM; CELL SPECIFICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HUMAN; NOTE; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WHOLE CELL; AGONISTS; BIOASSAY; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG RECEPTOR BINDING; DRUG SCREENING; PROCEDURES;

BIOLOGICAL ASSAY; DRUG AGONISM; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MODELS, BIOLOGICAL; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 77953184143     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00764.x     Document Type: Note

References (17)

1. Azzi M, Charest PG, Anger S, Rousseau G, Kohout T, Bouvier M (2003). β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc Natl Acad Sci USA 100 : 11406 11411.
2. Baker J (2010). The selectivity of β-adrenoceptor agonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 160 : 1048 1061.
3. Birdsall NJM, Hulme EC, Burgen ASV (1980). The character of the muscarinic receptors in different regions of the rat brain. Proc R Soc Lond B Biol Sci 207 : 1 12.
4. Black JW, Leff P (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220 : 141 162.
5. Fraunfelder H, Sligar SG, Wolynes PG (1991). The energy landscapes and motions of proteins. Science 254 : 1598 1603.
6. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70 : 1575 1158.
7. Hilser VJ, Garcia-Moreno EB, Oas TG, Kapp G, Whitten ST (2006). A statistical thermodynamic model of protein ensembles. Chem Rev 106 : 1545 1558.
8. Jakubic J, Bačáková L, El-Fakahany EE, Tuček S (1997). Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52 : 172 179.
9. Kenakin TP (2006). Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin Drug Discov 1 : 635 652.
10. Kenakin TP (2008). Pharmacological onomastics: what's in a name? Br J Pharmacol 153 : 432 438.
11. Kenakin TP (2009). Putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30 : 460 469.
12. Mailman RB (2007). GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28 : 390 396.
13. Onaran HO, Scheer A, Cotecchia S, Costa T (2002). A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor. In : Kenakin TP, Angus JA (eds). The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology, Vol. 148. Springer
14. Roth BL, Chuang D-M (1987). Multiple mechanisms of serotonergic signal transduction. Life Sci 41 : 1051 1064.
15. Trankle C, Weyand A, Schroter A, Mohr K (1999). Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine (m2) receptors. Mol Pharmacol 56 : 962 965.
16. Watson C, Chen G, Irving PE, Way J, Chen W-J, Kenakin TP (2000). The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58 : 1230 1238.
17. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM et al. (2003). Independent beta-arrestin 2 and G protein mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100 : 10782 10787.